Monte Rosa Therapeutics director sells $180,100 of Glue shares
Anthony M. Manning, a director at Monte Rosa Therapeutics, sold 10,000 shares of company stock for $180,100 after exercising stock options. Following the sale, Manning no longer directly holds common stock but retains 12,100 stock options. The sale occurred amidst a significant stock surge, and InvestingPro analysis suggests the stock is currently overvalued, despite positive clinical trial results for MRT-2359 and MRT-55811, and updated price targets from analysts.
Monte Rosa Therapeutics (GLUE) director exercises options and sells 10K shares
Monte Rosa Therapeutics director Anthony M. Manning exercised stock options to acquire 10,000 shares of common stock at $4.16 per share and subsequently sold all 10,000 shares in an open-market transaction at $18.01 per share on the same day. Following these transactions, Manning reported holding no common stock directly but retains stock options for 12,100 shares. The Form 4 filing details these insider transactions and Manning's remaining option holdings.
[144] Monte Rosa Therapeutics, Inc. SEC Filing
This article reports on a Form 144 SEC filing by Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), indicating a proposed sale of securities. The filing details include the sale of 2,176 common shares with an aggregate market value of $40,734.72, acquired through the exercise of stock options, with the sale scheduled for May 22, 2026, via UBS Financial Services, Inc. on NASDAQ.
[144] Monte Rosa Therapeutics, Inc. SEC Filing
This article announces a Form 144 SEC filing by Monte Rosa Therapeutics, Inc. (GLUE), indicating a proposed sale of 10,000 shares acquired through a stock option exercise by an individual. The aggregate market value of these shares is $180,100, and they will be sold on the NASDAQ. The filing includes details about the transaction and Filer, Issuer, and Securities Information.
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) announced its management will participate in two upcoming investor conferences: the TD Cowen 7th Annual Oncology Innovation Summit and the Jefferies Global Healthcare Conference. The company specializes in developing novel molecular glue degrader (MGD)-based medicines, utilizing its QuEEN™ discovery engine. Webcasts of the fireside chats will be available on Monte Rosa's investor relations website.
Biotech Monte Rosa lines up TD Cowen and Jefferies investor talks
Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotechnology company, announced its participation in two upcoming investor conferences: the TD Cowen 7th Annual Oncology Innovation Summit on May 27, 2026, and the Jefferies Global Healthcare Conference on June 4, 2026. Management will engage in fireside chats at these virtual and in-person events respectively, with webcasts and archives available on the company's investor relations website. The company specializes in developing molecular glue degrader medicines for serious diseases, utilizing its QuEEN™ discovery engine.
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics, a clinical-stage biotechnology company, announced its participation in two upcoming investor conferences: the TD Cowen 7th Annual Oncology Innovation Summit and the Jefferies Global Healthcare Conference. Management will engage in fireside chats at these events on May 27 and June 4, 2026, respectively. Webcasts of these presentations will be available on the company's website.
Vanguard Group Inc. Has $50.91 Million Position in Monte Rosa Therapeutics, Inc. $GLUE
Vanguard Group Inc. increased its stake in Monte Rosa Therapeutics (NASDAQ:GLUE) by 8.6% in Q4, holding 3,246,500 shares valued at approximately $50.9 million. This increase occurred despite the company reporting a weaker-than-expected quarter with an EPS of -$0.45 and revenue of $4.21 million, and ongoing insider selling by executives. Analysts currently rate GLUE as a "Moderate Buy" with a consensus price target of $32.50.
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Given Average Recommendation of "Moderate Buy" by Analysts
Monte Rosa Therapeutics (NASDAQ:GLUE) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $32.50. Despite this, the stock recently fell 2.8% after missing quarterly earnings and revenue estimates. Insider selling has also been noted, with executives selling shares worth approximately $668,694 in the last three months, though institutional investors hold a significant 79.96% stake.
[SCHEDULE 13G/A] Monte Rosa Therapeutics, Inc. Amended Passive Investment Disclosure
Baker Bros. Advisors and its affiliates have filed an amended Schedule 13G/A for Monte Rosa Therapeutics, Inc. (GLUE), reporting beneficial ownership of 8,876,346 shares, representing 9.99% of the common stock. This includes direct holdings and pre-funded warrants, with an increased Maximum Percentage for exercise from 4.99% to 9.99% effective March 25, 2026. The filing details the ownership structure and limitations on warrant exercise.
Monte Rosa Therapeutics (NASDAQ:GLUE) Given New $31.00 Price Target at JPMorgan Chase & Co.
JPMorgan Chase & Co. has raised its price target for Monte Rosa Therapeutics (NASDAQ:GLUE) to $31.00 from $30.00, maintaining an "overweight" rating. This new target implies a potential upside of 52.67% from the stock's current price, despite recent quarterly earnings missing analyst expectations. Other analysts have issued mixed ratings, with an overall "Moderate Buy" consensus and an average price target of $32.50.
Monte Rosa Therapeutics to detail new molecular glue degrader research at Endpoints webinar
Monte Rosa Therapeutics will host an Endpoints webinar to discuss its latest research on molecular glue degraders, specifically focusing on how cereblon interacts with various drug discovery targets. The event, scheduled for May 12th at 10:30 AM EDT, will feature Georg Petzold and Chao Quan. This presentation follows previous preclinical data shared by Monte Rosa on targeting CCNE1 in solid tumors and its CEO's participation in discussions on proximity-induced therapies, highlighting the company's continuous efforts in targeted protein degradation research.
A Look At Monte Rosa Therapeutics (GLUE) Valuation After Strong Recent Share Price Momentum
Monte Rosa Therapeutics (GLUE) has seen strong recent share price momentum, with a 15.7% return over the past month and 29.4% year-to-date. Despite this, its valuation presents mixed signals; a Price-to-Sales (P/S) multiple of 36.9x suggests overvaluation compared to the industry average and its own estimated fair P/S of 0.2x. However, a Discounted Cash Flow (DCF) model indicates the current $19.81 share price is significantly undervalued at 82.5% below its estimated fair value of $113.07.
Wedbush Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $37
Wedbush has reiterated its Buy rating on Monte Rosa Therapeutics (GLUE.US) and maintained its price target of $37. This continued positive outlook suggests the firm sees strong potential in the company.
Monte Rosa Therapeutics (NASDAQ:GLUE) Issues Quarterly Earnings Results, Misses Estimates By $0.06 EPS
Monte Rosa Therapeutics (NASDAQ:GLUE) announced its quarterly earnings, missing analyst estimates with an EPS of ($0.45) against an expected ($0.39), and revenue of $4.21 million compared to a $10.95 million consensus. Following the report, the stock dropped 2.1%. Despite the miss, analysts maintain a "Moderate Buy" rating with an average price target of $32.80, though some have recently adjusted their targets or ratings.
Monte Rosa (NASDAQ: GLUE) swings to Q1 loss but extends cash runway into 2029
Monte Rosa Therapeutics (NASDAQ: GLUE) reported a net loss of $44.5 million in Q1 2026, a significant shift from the $46.9 million net income in the prior year, primarily due to a sharp decline in collaboration revenue. Despite the loss and increased R&D expenses, the company maintains a strong liquidity position with $671.2 million in cash, cash equivalents, and marketable securities, projected to fund operations into 2029. The biotech firm's financial outlook is supported by recent equity offerings and ongoing collaborations with Roche and Novartis, which provide substantial funding for its molecular glue degrader programs.
Monte Rosa Therapeutics (GLUE) reports Q1 loss, misses revenue estimates
Monte Rosa Therapeutics (GLUE) reported a wider loss than anticipated for the first quarter, with a net loss of $0.66 per share, 9 cents higher than analyst estimates. The company also missed revenue expectations, recording $0.62 million against a forecast of $0.68 million. However, Monte Rosa's stock has shown significant year-to-date growth, outperforming the S&P 500.
Monte Rosa Therapeutics (GLUE) reports Q1 loss, misses revenue estimates
Monte Rosa Therapeutics (GLUE) reported a Q1 loss, failing to meet revenue estimates. The specific financial figures for the loss and revenue miss are not detailed in this snippet.
TD Cowen Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating
TD Cowen has reiterated its Buy rating on Monte Rosa Therapeutics (GLUE.US). This indicates a continued positive outlook from the firm regarding the company's stock performance.
Monte Rosa Therapeutics (GLUE) reports Q1 loss, misses revenue estimates
Monte Rosa Therapeutics (GLUE) reported a loss for the first quarter of the year, missing both Zacks Consensus Estimate and revenue expectations. The company posted a loss of $0.80 per share and revenues of $0.5 million, falling short of the estimated $1.2 million.
MONTE ROSA THERAPEUTICS ($GLUE) Releases Q1 2026 Earnings
MONTE ROSA THERAPEUTICS ($GLUE) reported its Q1 2026 earnings, missing both earnings per share and revenue estimates. The company reported EPS of -$0.45, below estimates of -$0.39, and revenue of $4.21 million, significantly under the $11.10 million estimate. Insider trading activity showed 11 sales and no purchases in the last six months, while institutional holdings saw a mix of additions and reductions.
Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q1 Revenue $4.2M, Vs. FactSet Est of $11.4M
Monte Rosa Therapeutics, Inc. (GLUE) announced its Q1 revenue, which came in at $4.2 million. This figure significantly missed the FactSet estimate of $11.4 million. The report indicates a substantial revenue shortfall for the quarter.
Monte Rosa (NASDAQ: GLUE) swings to Q1 2026 loss, builds cash runway into 2029
Monte Rosa Therapeutics reported a net loss of $44.5 million in Q1 2026, a swing from net income in Q1 2025, primarily due to normalized collaboration revenue after significant milestone payments in the prior year. Despite the revenue decline and increased operating expenses, the company strengthened its financial position with $671.2 million in cash and equivalents, projected to fund operations into 2029. Monte Rosa is also advancing multiple clinical programs, including several Phase 2 studies for MRT-8102 and MRT-2359, and anticipates new IND filings, supported by strong collaborations with Novartis and Roche.
Biotech Monte Rosa says its $671M cash pile funds operations into 2029
Monte Rosa Therapeutics announced its Q1 2026 financial results and business updates, revealing a strong cash position of $671.2 million, which is expected to fund operations into 2029. The company highlighted significant progress in its clinical programs, with MRT-8102, MRT-2359, and MRT-6160 all advancing towards Phase 2 trials and promising interim data in inflammatory diseases and metastatic castration-resistant prostate cancer. Despite a decrease in collaboration revenue and an increase in R&D expenses, the company's financial outlook remains positive due to a recent equity offering and potential milestones from its collaboration with Novartis.
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Monte Rosa Therapeutics reported its first-quarter 2026 financial results, highlighting significant progress across its clinical-stage pipeline. The company is advancing multiple molecular glue degrader (MGD) programs, with key readouts and Phase 2 study initiations anticipated for MRT-8102, MRT-6160 (in collaboration with Novartis), and MRT-2359. Monte Rosa ended the quarter with a strong cash position of $671 million, expected to fund operations into 2029.
Monte Rosa Therapeutics: Q1 Earnings Snapshot
Monte Rosa Therapeutics Inc. (GLUE) reported a first-quarter loss of $44.5 million, or 45 cents per share, missing Wall Street expectations. The biopharmaceutical company also reported revenue of $4.2 million, falling short of analysts' forecasts of $21.7 million. This financial performance indicates a challenging quarter for the Boston-based firm.
Monte Rosa Therapeutics: Q1 Earnings Snapshot
Monte Rosa Therapeutics Inc. reported a first-quarter loss of $44.5 million, or 45 cents per share, which missed Wall Street expectations. The biopharmaceutical company also reported revenue of $4.2 million, falling short of analysts' forecasts of $21.7 million.
Monte Rosa Therapeutics: Q1 Earnings Snapshot
Monte Rosa Therapeutics Inc. reported a Q1 loss of $44.5 million, or 45 cents per share, missing Wall Street's expectations. The biopharmaceutical company also recorded revenue of $4.2 million, which fell short of analyst forecasts of $21.7 million. This financial performance indicates a challenging quarter for the Boston-based firm.
Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q1 Revenue $4.2M, vs. FactSet Est of $11.4M
Monte Rosa Therapeutics, Inc. (GLUE) reported its Q1 revenue, coming in at $4.2 million, significantly below the FactSet estimate of $11.4 million. The report, published by MT Newswires, provides a quick financial update for the clinical-stage biotechnology company, which is focused on developing molecular glue degraders. The article also lists recent news and company information.
GLUE earnings ahead: Can Monte Rosa rebound from revenue miss?
Monte Rosa Therapeutics Inc. is expected to report its first-quarter earnings, with analysts forecasting a narrower loss and a significant revenue surge after a substantial miss in the previous quarter. Investors will be closely watching for a rebound in revenue and updates on its clinical programs, particularly the collaboration with Johnson & Johnson and Novartis, to assess if its scientific advancements are translating into financial traction. The company's stock currently holds a Strong Buy rating from all covering analysts, with a substantial implied upside.
Planned Monte Rosa (GLUE) CEO share sale under Rule 10b5-1
Monte Rosa Therapeutics President & CEO Markus Warmuth reported an open-market sale of 5,467 shares of common stock at a weighted average price of $18.922 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025. Following the sale, Warmuth directly holds 600,004 shares of Monte Rosa Therapeutics, indicating a planned adjustment rather than an opportunistic market timing.
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) announced inducement equity awards for four new non-executive employees. These awards include non-qualified stock options for 38,925 shares and restricted stock units for 8,550 shares, both vesting over several years. The grants were approved by the compensation committee and are in line with Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment.
Monte Rosa Therapeutics (GLUE) Is Down 5.0% After Cyclin E1 Degrader Data - Has The Bull Case Changed?
Monte Rosa Therapeutics (GLUE) saw a 5.0% stock drop despite presenting promising preclinical data for its cyclin E1-directed molecular glue degrader, MRT-55811, which showed tumor regression in CCNE1-amplified models. While this data validates their platform's potential for targeting "undruggable" oncogenes, the near-term investment narrative is more tied to clinical-stage assets like MRT-2359 and MRT-8102. Investors need to weigh the long-term thematic promise against recurring losses, recent equity dilution, and high expectations.
Form 144 | Monte Rosa Therapeutics(GLUE.US) Officer Proposes to Sell 103.45 Million in Common Stocks
An officer at Monte Rosa Therapeutics (GLUE.US) has filed a Form 144, indicating a proposed sale of common stocks valued at $103.45 million. This filing suggests a significant transaction by a company insider.
Monte Rosa Therapeutics (GLUE) Form 144: RSU 21,865; Markus Warmuth sales listed
A Monte Rosa Therapeutics (GLUE) Form 144 filing indicates a proposed sale of Common shares, detailing an RSU award of 21,865 shares dated 01/02/2025 with a related date of 01/02/2026. The filing also lists recent dispositions by Markus Warmuth, including a transaction on March 2, 2026, for $97,974.22 and a sale of 8,000 shares on April 14, 2026, for $141,124.80. Rockefeller Capital Management is named as the broker and NASDAQ as the market for the proposed sale.
GLUE SEC Filings - Monte Rosa Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Monte Rosa Therapeutics, Inc. (GLUE) SEC filings, including 10-K, 10-Q, and 8-K reports. It details how the biotechnology company uses these filings to disclose information about its clinical programs, financial condition, and material events. The platform also offers AI-powered summaries and impact analysis for these regulatory documents.
[ARS] Monte Rosa Therapeutics, Inc. SEC Filing
This article announces an ARS SEC filing by Monte Rosa Therapeutics, Inc. (GLUE), detailing its low impact and neutral sentiment, with an acceptance date of April 29, 2026. The filing is available as a PDF and originates from SEC EDGAR. The company's recent news and other SEC filings are also listed, alongside key stock data.
GLUE Price Today: Monte Rosa Therapeutics, Inc. Stock Price, Quote & Chart | MEXC
Monte Rosa Therapeutics, Inc. (GLUE) is currently trading at $19.31, reflecting a 2.37% decrease from its previous close. The stock has shown strong performance over the past year with a 290.06% price change, and a 24.33% return over the last month. The article provides key market data, a description of the company's biotechnology focus on molecular glue degraders, and FAQs for potential investors.
Monte Rosa Therapeutics, Inc. (GLUE) Presents at AACR Annual Meeting 2026 - Slideshow
Monte Rosa Therapeutics, Inc. (GLUE) presented a slideshow at the AACR Annual Meeting 2026. The article highlights this presentation and is attributed to Seeking Alpha's transcripts team, which covers numerous quarterly earnings calls. The company's stock symbol is GLUE.
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates
Monte Rosa Therapeutics (GLUE) reported a narrower-than-expected loss of $0.66 per share for the second quarter, surpassing the Zacks Consensus Estimate of a $0.78 loss. The company also beat revenue forecasts, reporting $2.5 million against an estimated $1.9 million. Despite these positive financial results, the article does not provide a specific date or timestamp for the earnings report beyond "2 days ago."
Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Tops Revenue Estimates
Monte Rosa Therapeutics (GLUE) reported a narrower-than-expected loss of $0.66 per share for Q2, beating the Zacks Consensus Estimate of a $0.72 loss. The company also surpassed revenue estimates, reporting $2.5 million against an expected $1.99 million. This performance represents significant year-over-year growth in both revenue and earnings.
Dimension funds and principals disclose stakes in Monte Rosa Therapeutics (NASDAQ: GLUE)
Dimension-related entities and affiliated individuals have filed an amended Schedule 13G/A, disclosing beneficial ownership in Monte Rosa Therapeutics (NASDAQ: GLUE). The filing indicates shared voting and dispositive power over 6,513,765 shares, representing an 8.1% stake based on 80,015,667 outstanding shares as of March 2, 2026. This disclosure clarifies the ownership structure and the individuals and entities involved in controlling these shareholdings.
What You Need To Know About The Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Analyst Downgrade Today
Analysts have significantly downgraded their near-term forecasts for Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), cutting revenue estimates sharply and increasing loss per share projections for 2026. The new consensus projects a disturbing 61% reduction in sales and a 229% increase in losses per share, indicating a much weaker outlook than previously anticipated. This downgrade suggests that investors should be wary, especially since the company's projected revenue decline is substantially worse than the wider industry's growth forecast.
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Monte Rosa Therapeutics (NASDAQ:GLUE) has received a consensus "Moderate Buy" rating from eight analysts, with an average 12-month price target of $32.80. This comes despite the company missing its Q4 2025 earnings and revenue estimates significantly, reporting an EPS of ($0.55) against ($0.45) expected and revenue of $2.78M against a $17.09M consensus. Insider sales were also noted, with the CEO and a director selling shares totaling approximately $668,694 in the last quarter, reducing insider ownership to 6.5%.
What You Need To Know About The Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Analyst Downgrade Today
Analysts have issued a major downgrade for Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), sharply cutting revenue forecasts for 2026 to US$48 million, down 61% from the previous year, and increasing loss per share estimates to US$1.59. This revised outlook, stemming from seven analysts, suggests a significantly weaker performance compared to both its historical growth and the broader biotech industry's projected revenue growth. The downgrade highlights concerns about the company's future financial performance and potential issues like significant stock dilution.
Monte Rosa presents preclinical data on cancer drug candidate
Monte Rosa Therapeutics announced positive preclinical data for MRT-55811, a molecular glue degrader targeting cyclin E1 (CCNE1), which induced tumor regressions in various CCNE1-amplified cancer models. The company's stock has surged over 330% in the past year, and analysts have issued a "strong buy" consensus, despite the stock trading above its fair value according to InvestingPro. Monte Rosa plans to submit an Investigational New Drug application for MRT-55811 later this year.
Monte Rosa drug shrank tumors in ovarian, breast and gastric models
Monte Rosa Therapeutics will present preclinical data on its CCNE1-directed molecular glue degrader, MRT-55811, at the AACR Annual Meeting 2026. The data shows potent and selective CCNE1 degradation and tumor regressions in ovarian, breast, and gastric cancer models, demonstrating superior selectivity compared to CDK2 inhibitors. The company plans to submit an Investigational New Drug (IND) application for MRT-55811 later in 2026, aiming to address critical unmet medical needs in CCNE1-amplified solid tumors.
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
Monte Rosa Therapeutics presented preclinical data at the AACR Annual Meeting 2026 on its Cyclin E1 (CCNE1)-directed molecular glue degrader (MGD). This MGD induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers. The company highlighted the MGD's superior selectivity and reduced off-target activity compared to CDK2 inhibitors.
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2026 on the Potential of its Cyclin E1 -directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
Monte Rosa Therapeutics announced preclinical data at the American Association for Cancer Research Annual Meeting 2026 for its cyclin E1 (CCNE1)-directed molecular glue degrader (MGD), MRT-55811. The data highlights MRT-55811's potential to treat CCNE1-amplified solid tumors, demonstrating deep tumor regressions in ovarian, breast, and gastric cancer models. The company plans to submit an IND for this program later this year, noting the MGD's superior selectivity compared to CDK2 inhibitors.
Monte Rosa presents preclinical data on cancer drug candidate By Investing.com
Monte Rosa Therapeutics (NASDAQ:GLUE) has announced positive preclinical data for its molecular glue degrader, MRT-55811, which targets cyclin E1 (CCNE1) in various cancers. The company's stock has seen significant growth, and analysts have issued "strong buy" recommendations, despite the stock trading above its fair value according to InvestingPro data. Monte Rosa continues to advance its clinical pipeline, with multiple programs progressing to Phase 2 studies and an Investigational New Drug application for MRT-55811 expected later this year.
